Page 26 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $7.20
52wk Low $0.72 Ensysce Biosciences, Inc. ENSC $0.69
7946 Ivanhoe Avenue
La Jolla, CA 92037

(USD - in millions) www.ensysce.com
Market Cap 5.5
Enterprise 4.9
Basic Shares Out. 7.33 COMPANY OVERVIEW
Float 7.14
Institutional Holdings 1.29% Detailed Analysis:Channelchek.com
Short Interest 0.02
Avg. 90-Day Volume 1.49 Ensysce Biosciences is a clinical-stage company using its proprietary
technology platforms to develop safer prescription drugs. Leveraging its
Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse
Resistance (MPAR®) platforms, the Company is developing unique,
EPS Data tamper-proof treatment options for pain that minimize the risk of both
drug abuse and overdose. Ensysce's products are anticipated to
2021 2022 2023 provide safer options to treat patients suffering from severe pain and
CQ1 N/A (14.40) (2.08) assist in preventing deaths caused by medication abuse. The platforms
CQ2 N/A (57.60) (0.98) are covered by an extensive worldwide intellectual property portfolio for
a wide array of prescription drug compositions.
CQ3 N/A (61.56) (0.87)
CQ4 (108.00) (74.28) (1.37)
CY (355.20) (139.44) (4.69) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) -0.10
ROE (ttm) NM
Debt-to-Total Cap. (mrq) 420.14
Fiscal Year End 31-Dec
7946 Ivanhoe La Jolla CA 92037

Key Executives
CEO: Kirkpatrick, D.
CFO: Humphrey, David
COO: Millard, Jeffrey
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures